

**efavirenz 600mg, emtricitabine 200mg, tenofovir disoproxil
245mg as fumarate (Atripla®) (No: 442/08)**

**Bristol Myers Squibb/Gilead Sciences/Merck Sharp &
Dohme Ltd**

Product Update

07 March 2008

The Scottish Medicines Consortium has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows:

ADVICE: following an abbreviated submission

efavirenz 600mg, emtricitabine 200mg, tenofovir disoproxil 245mg as fumarate (Atripla®) is accepted for use in NHS Scotland for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults with virologic suppression to HIV-1 RNA levels of < 50 copies/ml on their current combination antiretroviral therapy for more than three months. Patients must not have experienced virological failure on any prior antiretroviral therapy and must be known not to have harboured virus strains with mutations conferring significant resistance to any of the three components contained in this fixed dose combination prior to initiation of their first antiretroviral treatment regimen.

It may be used to simplify the regimen of patients for whom this combination is indicated (see above) and in whom all three agents are appropriate components at the doses provided by this fixed dose combination.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

This assessment is based on data submitted by the applicant company up to and including 16th January 2008.

Chairman, Scottish Medicines Consortium